Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

University of Saskatchewan

$18,500.00

Exploration of the lesser-known cannabinoids of Cannabis sativa

EF 2017-18

Résumé
The endocannabinoid system is broadly composed of endogenous cannabinoids; type 1 cannabinoid receptor (CB1R), type 2 cannabinoid receptor (CB2R), GPR18, GPR55, GPR119, and transient receptor potential cation channel subfamily V 1 (TRPV1), and multiple enzymes. The endocannabinoid system can be altered by plant-derived cannabinoids from Cannabis (marijuana) (a.k.a phytocannabinoids). The most well-known phytocannabinoids are d9-terahydrocannabinol (THC) and cannabidiol (CBD). Both THC and CBD are being intensively studied for their potential to treat chronic and acute pain, epilepsy, anxiety, and modulating appetite, among other effects. The pharmacology of THC is relatively well-established: THC is a CB1R and CB2R partial agonist and a GPR18 and GPR55 full agonist. The pharmacology of CBD is far-less clear. CBD has been described as a CB1R negative allosteric modulator, CB2R partial agonist, GPR18 agonist, and GPR55 antagonist, among other effects. Beyond THC and CBD there are at least 90 other phytocannabinoids found in marijuana. Examples of these lesser-known phytocannabinoids include tetrahydrocannabidiolic acid, tetrahydrocannabivarin (THCV), cannabigerol, cannabichromene, and cannabivarin (CBDV). Although some studies have already been conducted to demonstrate the potential medical value of a subset of these compounds - such as THCV and CBDV - in treating conditions such as epilepsy, the biology and receptor-mediated mechanism of action for most of these phytocannabinoids is unknown. The goal of this grant is to work in collaboration with CanniMed Therapeutics Inc. to isolate these lesser-known phytocannabinoids and discover their mechanism(s) of action. At a time when research is increasingly focused on the medicinal capabilities of Cannabis, this research offers a critical means of determining how the lesser-known cannabinoids, that is other than THC and CBD, affect cellular biology. This work will contribute to our understanding of how Cannabis affects the body in order to inform policy, harms reduction, and health choices.
Programme
Collaborative Research and Development Grants
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
517839-2017
Name nom
Laprairie, Robert
Department département
Pharmacy and Nutrition, College of
Organization id
16
Institution établissement
University of Saskatchewan
Province en
Saskatchewan
Province fr
Saskatchewan
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
18500
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
5407
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Receptors
Research subject fr
Récepteurs
Partie
1
Nb partie
2
Application title
Exploration of the lesser-known cannabinoids of Cannabis sativa
Keyword
NSERC
Application summary
The endocannabinoid system is broadly composed of endogenous cannabinoids; type 1 cannabinoid receptor (CB1R), type 2 cannabinoid receptor (CB2R), GPR18, GPR55, GPR119, and transient receptor potential cation channel subfamily V 1 (TRPV1), and multiple enzymes. The endocannabinoid system can be altered by plant-derived cannabinoids from Cannabis (marijuana) (a.k.a phytocannabinoids). The most well-known phytocannabinoids are d9-terahydrocannabinol (THC) and cannabidiol (CBD). Both THC and CBD are being intensively studied for their potential to treat chronic and acute pain, epilepsy, anxiety, and modulating appetite, among other effects. The pharmacology of THC is relatively well-established: THC is a CB1R and CB2R partial agonist and a GPR18 and GPR55 full agonist. The pharmacology of CBD is far-less clear. CBD has been described as a CB1R negative allosteric modulator, CB2R partial agonist, GPR18 agonist, and GPR55 antagonist, among other effects. Beyond THC and CBD there are at least 90 other phytocannabinoids found in marijuana. Examples of these lesser-known phytocannabinoids include tetrahydrocannabidiolic acid, tetrahydrocannabivarin (THCV), cannabigerol, cannabichromene, and cannabivarin (CBDV). Although some studies have already been conducted to demonstrate the potential medical value of a subset of these compounds - such as THCV and CBDV - in treating conditions such as epilepsy, the biology and receptor-mediated mechanism of action for most of these phytocannabinoids is unknown. The goal of this grant is to work in collaboration with CanniMed Therapeutics Inc. to isolate these lesser-known phytocannabinoids and discover their mechanism(s) of action. At a time when research is increasingly focused on the medicinal capabilities of Cannabis, this research offers a critical means of determining how the lesser-known cannabinoids, that is other than THC and CBD, affect cellular biology. This work will contribute to our understanding of how Cannabis affects the body in order to inform policy, harms reduction, and health choices.